COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis
USA - NASDAQ:COLL - US19459J1043 - Common Stock
35.76 USD
-0.34 (-0.94%)
35.76 USD
0 (0%)
COLL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. COLL has an excellent profitability rating, but there are some minor concerns on its financial health. COLL is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year COLL was profitable.
COLL had a positive operating cash flow in the past year.
Of the past 5 years COLL 4 years were profitable.
In the past 5 years COLL always reported a positive cash flow from operatings.
1.2 Ratios
COLL's Return On Assets of 2.28% is amongst the best of the industry. COLL outperforms 84.38% of its industry peers.
COLL has a better Return On Equity (15.62%) than 89.06% of its industry peers.
COLL has a better Return On Invested Capital (7.69%) than 84.90% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for COLL is below the industry average of 15.46%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.28% | ||
| ROE | 15.62% | ||
| ROIC | 7.69% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
With an excellent Profit Margin value of 5.13%, COLL belongs to the best of the industry, outperforming 83.85% of the companies in the same industry.
In the last couple of years the Profit Margin of COLL has declined.
With an excellent Operating Margin value of 18.35%, COLL belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
In the last couple of years the Operating Margin of COLL has grown nicely.
Looking at the Gross Margin, with a value of 56.69%, COLL is in the better half of the industry, outperforming 67.19% of the companies in the same industry.
COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.35% | ||
| PM (TTM) | 5.13% | ||
| GM | 56.69% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
COLL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for COLL has been reduced compared to 5 years ago.
COLL has a better debt/assets ratio than last year.
2.2 Solvency
COLL has an Altman-Z score of 1.14. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
COLL has a Altman-Z score (1.14) which is comparable to the rest of the industry.
The Debt to FCF ratio of COLL is 4.08, which is a neutral value as it means it would take COLL, 4.08 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.08, COLL belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
A Debt/Equity ratio of 3.27 is on the high side and indicates that COLL has dependencies on debt financing.
With a Debt to Equity ratio value of 3.27, COLL is not doing good in the industry: 80.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.27 | ||
| Debt/FCF | 4.08 | ||
| Altman-Z | 1.14 |
ROIC/WACC0.87
WACC8.81%
2.3 Liquidity
A Current Ratio of 1.18 indicates that COLL should not have too much problems paying its short term obligations.
COLL has a Current ratio of 1.18. This is in the lower half of the industry: COLL underperforms 78.13% of its industry peers.
COLL has a Quick Ratio of 1.10. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of COLL (1.10) is worse than 73.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.19% over the past year.
The Earnings Per Share has been growing by 154.78% on average over the past years. This is a very strong growth
COLL shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.61%.
Measured over the past years, COLL shows a quite strong growth in Revenue. The Revenue has been growing by 16.31% on average per year.
EPS 1Y (TTM)48.19%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%3.7%
Revenue 1Y (TTM)22.61%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%29.41%
3.2 Future
The Earnings Per Share is expected to grow by 4.42% on average over the next years.
COLL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.17% yearly.
EPS Next Y40.67%
EPS Next 2Y13.93%
EPS Next 3Y4.88%
EPS Next 5Y4.42%
Revenue Next Year19.33%
Revenue Next 2Y11.06%
Revenue Next 3Y4.61%
Revenue Next 5Y3.17%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
COLL is valuated cheaply with a Price/Earnings ratio of 5.46.
COLL's Price/Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 96.35% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.03, COLL is valued rather cheaply.
A Price/Forward Earnings ratio of 4.27 indicates a rather cheap valuation of COLL.
COLL's Price/Forward Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 96.88% of the companies in the same industry.
COLL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.27.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.46 | ||
| Fwd PE | 4.27 |
4.2 Price Multiples
COLL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. COLL is cheaper than 98.44% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 95.83% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.58 | ||
| EV/EBITDA | 4.76 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y13.93%
EPS Next 3Y4.88%
5. Dividend
5.1 Amount
No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
35.76
-0.34 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.73%
Inst Owner Change-1.26%
Ins Owners1.56%
Ins Owner Change1.27%
Market Cap1.13B
Revenue(TTM)707.01M
Net Income(TTM)36.27M
Analysts81.82
Price Target45.49 (27.21%)
Short Float %16.91%
Short Ratio13.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.92%
Min EPS beat(2)1.88%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)3.95%
Min EPS beat(4)-0.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.07%
EPS beat(12)9
Avg EPS beat(12)-6.79%
EPS beat(16)9
Avg EPS beat(16)-27.3%
Revenue beat(2)2
Avg Revenue beat(2)1.62%
Min Revenue beat(2)1.34%
Max Revenue beat(2)1.9%
Revenue beat(4)3
Avg Revenue beat(4)0.71%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.9%
Revenue beat(8)3
Avg Revenue beat(8)-0.65%
Revenue beat(12)6
Avg Revenue beat(12)-0.42%
Revenue beat(16)7
Avg Revenue beat(16)-4.84%
PT rev (1m)0%
PT rev (3m)3.72%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)15.03%
EPS NY rev (1m)7.69%
EPS NY rev (3m)29.1%
Revenue NQ rev (1m)-0.95%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.46 | ||
| Fwd PE | 4.27 | ||
| P/S | 1.59 | ||
| P/FCF | 5.58 | ||
| P/OCF | 5.54 | ||
| P/B | 4.85 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.76 |
EPS(TTM)6.55
EY18.32%
EPS(NY)8.37
Fwd EY23.41%
FCF(TTM)6.41
FCFY17.92%
OCF(TTM)6.46
OCFY18.06%
SpS22.44
BVpS7.37
TBVpS-22.1
PEG (NY)0.13
PEG (5Y)N/A
Graham Number32.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.28% | ||
| ROE | 15.62% | ||
| ROCE | 11.5% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.58% | ||
| ROICexgc | N/A | ||
| OM | 18.35% | ||
| PM (TTM) | 5.13% | ||
| GM | 56.69% | ||
| FCFM | 28.54% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.27 | ||
| Debt/FCF | 4.08 | ||
| Debt/EBITDA | 2.22 | ||
| Cap/Depr | 0.79% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | 1.9 | ||
| Cash Conversion | 59.64% | ||
| Profit Quality | 556.38% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 1.14 |
F-Score5
WACC8.81%
ROIC/WACC0.87
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.19%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%3.7%
EPS Next Y40.67%
EPS Next 2Y13.93%
EPS Next 3Y4.88%
EPS Next 5Y4.42%
Revenue 1Y (TTM)22.61%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%29.41%
Revenue Next Year19.33%
Revenue Next 2Y11.06%
Revenue Next 3Y4.61%
Revenue Next 5Y3.17%
EBIT growth 1Y-36.29%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year149%
EBIT Next 3Y27.45%
EBIT Next 5Y16.08%
FCF growth 1Y-14.2%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y-13.96%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 7 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 4 / 10.